Biotech unicorn Oxford Nanopore raises £195M ahead of London IPO; valued at £2.48B

Funding Rounds

▤ Summary

Notably, the company is also planning to list on the London stock market in the second half of this year as well. Founded by Hagan Bayley in 2005, Oxford Nanopore has developed and commercialises a novel generation of DNA/RNA sequencing technology that provides rich data, is fast, accessible, and easy to use in any location. The University of Oxford spin-off now employs more than 600 people from multiple disciplines including nanopore science, molecular biology, and applications, informatics, engineering, electronics, manufacturing, and commercialisation. The palm-sized portable MinION device, and desktop GridION and PromethION devices, are used in a broad range of scientific analyses, across human genetics, cancer research, agriculture, food safety, healthcare, and environmental insights. Most recently, Oxford Nanopore has launched the MinION Mk1C, a fully connected sequencer with screen and compute, and has also developed the LamPORE COVID-19 test.

$ Funding

$
Amount $270.6M Total raised
□
Date May 4, 2021 Announcement date
◎
Investors Oxford Nanopore Technologies Lead investors
▥
Company http://www.nanoporetech.com Funded company

▥ Classifications

industries
No industries detected
applications
Data Management

◇ AskAI Classifications

Labels
Biotechnology Software SaaS

▦ Linked Companies